Rockwell Medical, Inc.
1.0900-0.03 (-2.68%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · RMTI · USD
Key Stats
Market Cap
37.53MP/E (TTM)
-Basic EPS (TTM)
-0.07Dividend Yield
0%Recent Filings
8-K
Hunter promoted to COO
Rockwell Medical appointed Heather Hunter as Senior Vice President and Chief Operating Officer on September 23, 2025, promoting her from Chief Corporate Affairs Officer. Hunter, 46, brings extensive experience from Venatorx Pharmaceuticals and Safeguard Scientifics, with her employment agreement offering a $323,574 base salary, 45% target bonus, and an initial 60,000-share option grant. This move bolsters operational leadership amid the company's healthcare focus. Yet, change-of-control provisions heighten executive retention risks.
8-K
Q2 sales drop, new contracts signed
Rockwell Medical reported Q2 2025 net sales of $16.1 million, down 38% from $25.8 million in 2024, as its largest customer transitioned away, yet gross margin held at 16% while generating $1.8 million in operating cash flow. The company inked multi-year deals with major U.S. dialysis providers like Innovative Renal Care, securing over 80% of customers under long-term contracts. Cash swelled to $18.4 million. New wins stabilize revenue, but sales dip lingers.
10-Q
Q2 FY2025 results
Rockwell Medical's Q2 revenue fell 38% y/y to $16.1M, driven by a $9.9M drop in DaVita sales amid their supplier transition, though non-refundable DaVita payments added $0.3M; gross profit slid 45% to $2.5M with margins dipping to 16% from 18%. Operating loss widened to $1.3M from $0.5M profit, while YTD revenue declined 28% to $35.0M and net loss reached $3.0M or $(0.09) diluted EPS on 34.2M shares. Cash and equivalents stood at $12.5M with $5.9M in short-term investments, supporting $20.7M working capital; term debt was $8.6M at 11.0% effective rate, maturing 2029 with interest-only payments through 2027. The 2023 Evoqua asset acquisition added $9.9M in customer intangibles amortized over 20 years, with $0.9M deferred consideration paid YTD. Customer concentration remains a risk, as DaVita's exit could pressure volumes further.
8-K
Annual meeting elects directors
Rockwell Medical's stockholders, at the May 20, 2025 annual meeting, elected John G. Cooper and Allen Nissenson, MD, as Class I directors for three-year terms, with strong support exceeding 95% of votes cast. They approved executive compensation on an advisory basis and ratified EisnerAmper LLP as auditors for 2025, while endorsing an amendment to the 2018 Long Term Incentive Plan adding 5 million shares for issuance. This bolsters governance continuity. Yet, broker non-votes hit 8.4 million shares.
8-K
Q1 sales drop, margins rise
Rockwell Medical reported Q1 2025 net sales of $18.9 million, down 17% from $22.7 million in Q1 2024, due to its largest customer switching suppliers, offset by a $0.9 million one-time payment for supply continuity. Gross profit held steady at $3.0 million, boosting gross margin to 16% from 14%, while net loss improved 12% to $1.5 million. The company added a bicarbonate cartridge to its portfolio via a new distribution deal. Cash dipped to $17.3 million from $21.6 million year-end. Rockwell confirms 2025 guidance: net sales $65-70 million, gross margin 16-18%, adjusted EBITDA ($0.5)-$0.5 million. Customer loss stings, yet margins endure.
IPO
Website
Employees
Sector
Industry
DERM
Journey Medical Corporation
7.94-0.19
DVA
DaVita Inc.
126.56-3.05
FMS
Fresenius Medical Care AG
26.90-0.19
LFCR
Lifecore Biomedical, Inc.
7.06+0.16
MRMD
MariMed Inc.
0.13+0.00
NEPH
Nephros, Inc.
5.45-0.29
NUWE
Nuwellis, Inc.
3.05-0.05
RDY
Dr. Reddy's Laboratories Ltd
13.41-1.19
RMTG
Regenerative Medical Technology
0.05+0.00
ROK
Rockwell Automation, Inc.
368.15+6.17